The implant is intended for osteochondral lesions of the talar dome of the ankle joint. The new ankle implant is supplied together with a kit of surgical tools, and the devices are based on the same technology platform as the company's Episealer® knee devices, with an individualised design based on medical imaging and 3D modulation.
"We believe this is a world-unique implant solution and we are very happy to add Episealer® Talus to our product portfolio" says Pål Ryfors, CEO
"This device is a next step in the treatment of patients with large secondary osteochondral defects both on the medial or lateral side of the talar dome. It offers a tailor-made solution for these otherwise difficult to treat lesions" says Prof. dr.
In connection with this, the company has a parallel process to receive CE mark for an individualised osteotomy guide that is intended to help surgeons to find the correct position and depth of the sawing when performing a medial malleolar osteotomy.
Pål Ryfors continues: "With the addition of the Episealer® Talus to our product portfolio, we are now expanding outside the knee joint and offer treatment options for focal articular defects of the femoral knee joint as well as medial and lateral positions of the ankle joint. We are very excited that our new product line will finally be available on the market. Surgeons have indicated the need and are eager to get started. We will, of course, inform the market once the final certificate is issued, but today's information was critical to us and to this process".
[Pl Ryfors CEO
For more information, please contact:
Pål Ryfors, CEO,
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About
This information is information that
https://news.cision.com/episurf/r/ce-marking-for-the-episealer---talus-implant-expected-for-episurf-medical,c3000816
https://mb.cision.com/Main/14691/3000816/1169403.pdf
https://news.cision.com/episurf/i/pal-ryfors-20200102,c2732241
(c) 2020 Cision. All rights reserved., source